Company
Astellas
Astellas has 53 drugs tracked on RxWires: 12 post-market, 2 approved, 11 in Phase 3, 7 in Phase 2, 5 in Phase 1/2, 14 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Solifenacin succinate | Post-Market | Over-Active Bladder |
| Tacrolimus | Post-Market | Kidney Transplantation |
| Tacrolimus granules | Post-Market | Liver Transplantation |
| ramosetron, aprepitant, dexamethasone | Post-Market | Cancer |
| avacincaptad pegol | Post-Market | Geographic Atrophy |
| Advagraf | Post-Market | Kidney Transplantation |
| Tacrolimus targeted half-dose | Post-Market | De Novo Transplant Disease |
| Beraprost | Post-Market | Type 2 Diabetes Mellitus |
| zolpidem | Post-Market | Insomnia |
| Gabapentin enacarbil | Post-Market | Restless Legs Syndrome (RLS) |
| Astagraf XL | Post-Market | End Stage Renal Disease |
| fidaxomicin | Post-Market | Inflammatory Bowel Disease (IBD) |
| ARISTOGEL | Approved | |
| CYCLOCORT | Approved | |
| fezolinetant | Phase 3 | Hot Flashes |
| ASP2138 | Phase 3 | Gastric Adenocarcinoma |
| CZP | Phase 3 | Rheumatoid Arthritis |
| gilteritinib | Phase 3 | Acute Myeloid Leukemia |
| zolbetuximab | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer |
| Setidegrasib | Phase 3 | Pancreatic Cancer |
| Enfortumab vedotin | Phase 3 | Urothelial Cancer |
| ipragliflozin | Phase 3 | Type 2 Diabetes Mellitus |
| FK506E (modified release tacrolimus) | Phase 3 | Liver Transplantation |
| enzalutamide | Phase 3 | Adenocarcinoma of the Prostate |
| Peficitinib | Phase 3 | Rheumatoid Arthritis (RA) |
| ADT+Docetaxel+Enzalutamide | Phase 2 | Prostate Cancer |
| Erlotinib Hydrochloride | Phase 2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Rapamycin | Phase 2 | Type 1 Diabetes |
| Tacrolimus Inhalation Aerosol | Phase 2 | Asthma |
| ASP6294 | Phase 2 | Bladder Pain Syndrome |
| ASKP1240 | Phase 2 | Psoriasis |
| ASP1941 | Phase 2 | Diabetes Mellitus, Type 2 |
| zocaglusagene nuzaparvovec | Phase 1/2 | Pompe Disease (Late-onset) |
| ASP9521 | Phase 1/2 | Castrate Resistant Prostate Cancer |
| ASP2957 | Phase 1/2 | X-Linked Myotubular Myopathy |
| ASP388B | Phase 1/2 | Locally Advanced or Metastatic Solid Tumors |
| YM 155 | Phase 1/2 | Prostate Cancer |
| ASP2390 | Phase 1 | Allergic to House Dust Mites |
| 14C-labeled YM178 | Phase 1 | Metabolic Processes |
| ASP2020 | Phase 1 | Stargardt Disease |
| ASP5541 | Phase 1 | Prostate Cancer |
| VIR-5500 | Phase 1 | Hormone-refractory Prostate Cancer |
| 14C-labeled ASP3082 | Phase 1 | |
| ASP5834 | Phase 1 | Solid Tumor |
| ASP3652 | Phase 1 | Pharmacokinetics of ASP3652 |
| radio-labeled OSI-906 | Phase 1 | Advanced Solid Tumors |
| Isavuconazole | Phase 1 | Pharmacokinetics of Isavuconazole |
| 14C-labeled prodrug isavuconazonium sulfate | Phase 1 | Pharmacokinetics of 14C-labeled Isavuconazole |
| Roxadustat | Phase 1 | Normal Renal Function |
| mirabegron | Phase 1 | Cardiovascular |
| AGS-8M4 | Phase 1 | Carcinoma |
| regadenoson | Not Applicable | Cardiac Function |
| tamsulosin 0.4mg | Not Applicable | Prostatic Neoplasms, Prostatectomy |
Latest
No recent events.
Follow Astellas on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.